Glenmark to end FY21 with better margins led by low expenses, India sales growth and US business rebound

The company said the worst is behind in terms of US business and expects an uptick in sales from Q3FY21 onwards.

Glenmark Consolidated June 2020 Net Sales at Rs 2,344.79 crore, up 0.94% Y-o-Y

Glenmark Standalone June 2020 Net Sales at Rs 1,682.92 crore, up 12.29% Y-o-Y

Glenmark to launch higher strength of FabiFlu

The higher strength will improve compliance for patients by effectively reducing the number of tablets required per day, Glenmark said in a statement.

Coronavirus treatment | FabiFlu much more affordable than other options: Glenmark tells DCGI

On July 13, Glenmark Pharmaceuticals cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, by 27 percent to Rs 75 per tablet.

Glenmark Standalone March 2020 Net Sales at Rs 1,607.73 crore, up 1.29% Y-o-Y

Glenmark Consolidated March 2020 Net Sales at Rs 2,767.49 crore, up 7.96% Y-o-Y

HUL completes acquisition of female hygiene brand VWash from Glenmark

The acquisition was announced in March and was subject to certain closing conditions, which have now been fulfilled, the FMCG firm said in a filing to BSE.

Coronavirus pandemic | Glenmark launches COVID-19 drug FabiFlu after DCGI nod

FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.

Glenmark gets USFDA nod to market generic drug for muscle pain

Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Chlorzoxazone tablets USP, in strength of 375 mg and 750 mg, the drug maker said in a statement.

Glenmark initiates Phase 3 clinical trials on Favipiravir to check efficacy on COVID-19 patients

The Mumbai-based company had received approval from Drug Controller General of India (DCGI) last month to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.

Glenmark launches 3-in-1 inhaler for COPD patients in India

Glenmark Pharmaceuticals on Monday said it has launched a triple therapy inhaler in the country for patients with chronic obstructive pulmonary disease (COPD).

Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients

Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, Glenmark Pharmaceuticals said in a statement.

Hindustan Unilever snaps up Glenmark-owned VWash

The transaction is subject to fulfilment of certain conditions and both the companies are looking to seal the deal in the next few months.

Deleveraging and deals – a healthy prescription for pharma sector

A stronger domestic market foundation helps as a buffer from fluctuating US sales.

Glenmark gets USFDA nod for generic acne treatment gel

The approval granted to Glenmark Pharmaceuticals Inc by the US Food and Drug Administration is for Adapalene and Benzoyl Peroxide Gel, 0.1 per cent/2.5 per cent, which is the the generic version of Epiduo gel, 0.1 per cent/2.5 per cent of of Galderma Laboratories LP, the company said in a statement.

Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay

Net Sales are expected to increase by 2.4 percent Y-o-Y (up 13.8 percent Q-o-Q) to Rs. 2,642.7 crore, according to Emkay.

Glenmark gets tentative nod from USFDA for generic multiple sclerosis treatment drug

The tentative nod granted by US Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc, USA (Glenmark) is for multiple strengths of dimethyl fumarate delayed-release capsules of 120 mg and 240 mg.

Pharma wrap: No respite for Glenmark, USFDA’s warning letter on Baddi facility adds to woes

The warning letter comes at a time when the company has been struggling with high debt and lack of meaningful approvals for products that can shore-up declining US sales

USFDA issues warning letter to Glenmark for its Baddi facility

The company believes that the existing manufacturing and the sale of products from this facility will not be impacted, it added.

Buy Glenmark; target of Rs 500: HDFC Securities

HDFC Securities is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 500 in its research report dated August 16, 2019.

Glenmark Pharma pins hope on sale of non-core assets, stake sale in spun-off R&D unit to pare debt

Glenmark is struggling with high debt, lack of meaningful approvals to shore-up declining US sales and delays in commercialization of specialty anti-allergy nasal spray Ryaltris.

Market Headstart: Nifty50 seen opening higher; 3 stocks which could give 5-10% return

Trends on SGX Nifty indicate a higher opening for the broader index in India, a gain of 41 points or 0.35 percent. Nifty futures were trading around 11,643-level on the Singaporean Exchange.

Will Glenmark's attempts to unlock value of API, R&D units prove beneficial?

Given its high spend on drug development and investment on capex over the years, Glenmark had amassed huge debt.

Glenmark Standalone March 2019 Net Sales at Rs 1,587.28 crore, down 4.82% Y-o-Y